An update on generalized pustular psoriasis
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Introduction: Generalized pustular psoriasis (GPP) is a rare, severe relapsing/remitting, multisystem disease that can be difficult to treat. Recent clinical, histological, and genetic evidence suggests that GPP is a distinct clinical entity from plaque psoriasis and requires a separate diagnosis. The interleukin-36 pathway appears to be central to GPP pathogenesis. As no therapeutic agents have been approved for GPP to date in the United States or Europe, the introduction of anti-IL-36 therapies may change disease management. Areas covered: Using PubMed and Google Scholar, we reviewed the literature for articles related to GPP, psoriasis, and the genetics, pathogenesis, and treatment thereof. Expert opinion: New therapeutic options and updated guidelines for GPP treatment are needed. Ideal agents would have rapid onset of action and rapid time to achieve disease clearance, have the ability to prevent acute flares and avert recurrence, and possess a favorable safety profile. Such therapies should be readily accessible via approval or listing on formularies. Scoring systems to establish GPP disease burden and objective outcome measures could also help with further evaluation of therapies and treatment access issues. IL-36 remains a promising target, as supported by early phase data suggesting efficacy and safety for a novel anti-IL-36 therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Severe Psoriasis – Oral Therapy with a New Retinoid
Fredriksson, T., & Pettersson, U. (2009) · Dermatologica · doi:10.1159/000250839 · Cited by 2,718 · cited 3×
“The Generalized Pustular PASI (GPPASI) replaces the induration component with a pustule component, while the Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) is a clinical assessment of the severity of pustules, erythema, and scaling of GPP lesions [92].”
MethodSecukinumab in plaque psoriasis—results of two phase 3 trials
Langley, R. G., Elewski, B. E., Lebwohl, M., Reich, K., Griffiths, C. E. M., Papp, K., Puig, L., Nakagawa, H., Spelman, L., Sigurgeirsson, B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314258 · Cited by 1,997
Inhibition of the Interleukin-36 Pathway for the Treatment of Generalized Pustular Psoriasis
Bachelez, H., Choon, S.-E., Marrakchi, S., Burden, A. D., Tsai, T.-F., Morita, A., Turki, H., Hall, D. B., Shear, M., Baum, P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmc1811317 · Cited by 292 · cited 3×
“The importance of targeting IL-36R signaling in GPP is supported by a recent phase 1 study (N = 7) that reported good efficacy and safety was shown by anti-IL-36R agent BI 655130 [92].”
BackgroundKhalil, S., Bardawil, T., Stephan, C., Darwiche, N., Abbas, O., Kibbi, A. G., Nemer, G., & Kurban, M. (2017) · Journal of Dermatological Treatment · doi:10.1080/09546634.2017.1309349 · Cited by 217 · cited 1×
“Oral retinoids are contraindicated in women who are pregnant or who may become pregnant [76].”
Background
Cited by
Deep Learning Application for Effective Classification of Different Types of Psoriasis
Aijaz, S. F., Khan, S. J., Azim, F., Shakeel, C. S., & Hassan, U. (2022) · Journal of Healthcare Engineering · doi:10.1155/2022/7541583 · Cited by 77
Metadata
- Authors
- Gooderham, M. J., Van Voorhees, A. S., & Lebwohl, M. G.
- Venue
- Expert Review of Clinical Immunology
- Publisher
- Informa UK Limited
- Published
- 2019-09-02
- Volume
- 15
- Issue
- 9
- Pages
- 907-919
- ISSN
- 1744-666X (ISSN-L)
- 1744-8409
- OpenAlex
- W2971667944
- Cited by
- 226
- References
- 4
- FWCI
- 6.33
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An update on generalized pustular psoriasis. https://app.cochat.ai/papers/10.1080/1744666x.2019.1648209
- The paper
- Gooderham, M. J., Van Voorhees, A. S., & Lebwohl, M. G. (2019). An update on generalized pustular psoriasis. Expert Review of Clinical Immunology. https://doi.org/10.1080/1744666x.2019.1648209
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.